{"url_path":"/sec/hlyk/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 Unregistered Sales of Equity Securities","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1680139/0001213900-26-057581-index.html","accession_number":"0001213900-26-057581","cik":"0001680139","ticker":"HLYK","issuer_name":"HealthLynked Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/1680139/0001213900-26-057581-index.html","primary_entity_key":"0001680139","primary_entity_name":"HealthLynked Corp"},"word_count":847,"has_tables":true,"body_markdown":"**Item 2. Unregistered Sales of Equity Securities\nand Use of Proceeds**\n\n \n\nExcept as previously disclosed\nin a Current Report on Form 8-K or in a Form 10-Q or 10-K, or as set forth below, the Company has not sold securities that were not registered\nunder the Securities Act of 1933, as amended (the “Securities Act”), during the period covered by this report:\n\n \n\nOn January 14, 2026, we issued\nto Jason Bishara, one of our Directors, a convertible note with principal of $25,000, an interest rate of 12% per annum, and a maturity\ndate of January 14, 2027. The note is convertible into shares of our common stock at a fixed conversion price of $3.00 per share. We received\nnet proceeds of $25,000. In connection with the note, we also issued Mr. Bishara a five-year warrant to purchase 8,333 shares of our common\nstock at an exercise price of $3.00 per share.\n\n \n\nOn January 14, 2026, we issued\nto an investor a convertible note with principal of $25,000, an interest rate of 12% per annum, and a maturity date of January 14, 2027.\nThe note is convertible into shares of our common stock at a fixed conversion price of $3.00 per share. We received net proceeds of $25,000.\nIn connection with the note, we also issued the investor a five-year warrant to purchase 8,333 shares of our common stock at an exercise\nprice of $3.00 per share.\n\n \n\nOn January 21, 2026, we issued\na promissory note to an investor with a stated principal amount of $151,800 and prepaid interest of $18,216 for total repayments of $170,016.\nWe received net proceeds of $25,000 after original issue discount of $19,800 and fees of $7,000. The note does not bear interest in excess\nof the original issue discount and prepaid interest and matures on November 15, 2026. We are required to make an initial payment of $85,008\non July 15, 2026 and four monthly payments of $21,252 starting August 15, 2026 and ending on November 15, 2026. The note gives the holder\na conversion right at a 35% discount to the market price of our common stock only in the event of default.\n\n \n\nOn January 22, 2026, we issued\na convertible promissory note to an investor with a stated principal amount of $240,000, an interest rate of 12% per annum and maturity\nupon the earlier of (i) six months from the issue date or upon a US senior exchange listing. The note is convertible into shares of our\ncommon stock at a fixed conversion price of $6.07 per share. We received net proceeds of $200,000 after original issue discount of $40,000.\nThe note gives the holder a conversion right at a 20% discount to the market price of our common stock only in the event of default. In\nconnection with the note, we also issued the investor a five-year warrant to purchase 32,249 shares of our common stock at an exercise\nprice of $6.07 per share.\n\n \n\nOn January 27, 2026, we issued\na promissory note to an investor with a stated principal amount of $151,800 and prepaid interest of $18,216 for total repayments of $170,016.\nWe received net proceeds of $25,000 after original issue discount of $19,800 and fees of $7,000. The note does not bear interest in excess\nof the original issue discount and prepaid interest and matures on November 15, 2026. We are required to make an initial payment of $85,008\non July 15, 2026 and four monthly payments of $21,252 starting August 15, 2026 and ending on November 15, 2026. The note gives the holder\na conversion right at a 35% discount to the market price of our common stock only in the event of default.\n\n \n\nOn February 2, 2026, the Company\nrefinanced all past outstanding notes with aggregate principal totaling $4,338,192, accrued interest totaling $737,180, undocumented advances\ntotaling $339,840 and accrued compensation liabilities totaling $300,600 into a new consolidated Secured Convertible Promissory Note in\nthe principal amount of $5,715,812 payable to a trust controlled by Dr. Michael Dent (the “February 2026 Dent Note”). The\nFebruary 2026 Dent Note accrues interest at a rate of 12% per year and matures on February 2, 2029, at which time all outstanding principal\nand interest is due. The February 2026 Dent Note is convertible into shares of common stock at any time at the holder’s discretion\nat a conversion price of $4.25 per share, subject to adjustment in the event of a future offering by the Company at a price lower than\nthe conversion price.\n\n \n\nOn February 27, 2026, we issued\n60,000 shares to a consultant for services performed.\n\n \n\nThe sales of the above securities\nwere exempt from registration under the Securities Act in reliance upon Section 4(a)(2) of the Securities Act, as transactions by an issuer\nnot involving any public offering. The recipients of the securities in each of these transactions represented their intentions to acquire\nthe securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends\nwere placed upon the stock certificates issued in these transactions.\n\n \n\n40"}